Loucas S P, Mehl B, Maager P, Litwak R S, Jurado R A
Am J Hosp Pharm. 1981 Dec;38(12):1924-8.
The stability of procaine hydrochloride in a buffered cardioplegia solution was studied. The formulation of Ringer's injection with added increments of potassium and magnesium plus procaine hydrochloride was buffered to a pH of 7.3-7.6 with tromethamine. Procaine hydrochloride content was measured in triplicate by ultraviolet spectrophotometry at set time intervals and at temperatures of 22, 40, and 61 degrees C. The time required for procaine to degrade to the lower shelf-life limit of 90% of its initial concentration was extrapolated to be approximately two days at room temperature and 11 days under refrigeration. It is recommended that the basic buffered cardioplegia solvent be manufactured separately, and the procaine hydrochloride be added at the time of dispensing to minimize its loss of potency.
研究了盐酸普鲁卡因在缓冲心脏停搏液中的稳定性。在林格氏注射液中添加递增剂量的钾、镁以及盐酸普鲁卡因，并用三羟甲基氨基甲烷将其缓冲至pH 7.3 - 7.6。在设定的时间间隔以及22℃、40℃和61℃温度下，通过紫外分光光度法对盐酸普鲁卡因含量进行了三次测定。推算出在室温下盐酸普鲁卡因降解至其初始浓度的90%这一较低货架期限值所需的时间约为两天，冷藏条件下为11天。建议分别制备碱性缓冲心脏停搏溶剂，并在调配时添加盐酸普鲁卡因，以尽量减少其效力损失。
